Healthcare Industry Developments | BioTuesdays by Kilmer Lucas IR

Developments

BioRestorative Therapies gains media attention for key regenerative medicine programs

Benzinga editor, Tony Noto, interviewed Lance Alstodt, BioRestorative’s (NASDAQ:BRTX) Chief Executive Officer, about the company’s two core clinical development programs (BRTX-100 targeting disc/spine disease and...

June 20, 2024

Developments

OneMedNet forges alliance with clinical trial design and software global leader

OneMedNet (NASDAQ:ONMD) announced that it has entered into a significant iRWD customer data licensing agreement, partnering with an undisclosed U.S.-based global leader in clinical trial design and software with...

June 14, 2024

Developments

Former Hepion CEO sues over departure; cites bad faith dealings with investor

Former Hepion Pharmaceuticals (NASDAQ:HEPA) CEO, Robert Foster, PharmD, PhD, is suing the company and its Board members for illegal termination of his employment, breach of contract, and breach of the covenant of good...

June 13, 2024

Developments

BioRestorative in substantive discussions with prospective licensing partner for ThermoStem metabolic disease program

BioRestorative Therapies (NASDAQ:BRTX) reports that it is engaged in substantive discussions with an undisclosed commercial stage regenerative medicine company concerning the licensing of its proprietary off-the-shelf...

June 13, 2024

Developments

Sage’s Phase 2 SURVEYOR study meets primary endpoint; reinforces cognitive impact of Huntington’s disease

Sage Therapeutics (NASDAQ:SAGE) announced its Phase 2 SURVEYOR study has met its primary endpoint showing a significant difference in HD-Cognitive Assessment Battery composite scores at baseline between healthy...

June 11, 2024

Developments

Viridian reports details of SC VRDN-003 Phase 3 clinical program for patients with TED

Viridian Therapeutics (NASDAQ:VRDN) announced details of its plans to initiate two Phase 3 clinical trials of its subcutaneous VRDN-003 product candidate for patients with active and chronic moderate-to-severe thyroid...

June 11, 2024

Developments

OneMedNet joins AWS partner network as it enters into a “stage of anticipated rapid growth”

OneMedNet (NASDAQ:ONMD) announced that it has joined the Amazon Web Services (AWS) Partner Network (APN), significantly expanding industry access to its proprietary iRWD platform and securing an undisclosed...

June 6, 2024

Developments

Inogen shares published study results demonstrating association of portable oxygen therapy with increased survival and cost-effectiveness

Inogen (NASDAQ:INGN) reported that the peer-reviewed journal, Pulmonary Therapy, has published a study demonstrating the association of portable oxygen concentrators with decreased mortality and increased cost...

June 5, 2024

Developments

Innate Pharma announces positive outcomes from TELLOMAK Phase 2 Study

Innate Pharma S.A. (Euronext Paris:IPH; Nasdaq:IPHA) presented positive results from its Phase 2 TELLOMAK study with lacutamab in mycosis fungoides at the ASCO 2024 Annual Meeting in Chicago. The company reported that...

June 5, 2024

Developments

Trinity Biotech unveils new microsite to highlight distinctive technology and AI-driven platform

Trinity Biotech (NASDAQ: TRIB) has announced the launch of its continuous glucose monitoring (CGM) microsite to provide insights into the development of its next-generation CGM biosensor technology and AI-driven health...

June 3, 2024

Developments

Verve Therapeutics appoints Troy Lister as CSO

Verve Therapeutics (NASDAQ:VERVE) has appointed Troy Lister, Ph.D., as CSO, effective June 21, 2024, succeeding Andrew Bellinger, M.D., Ph.D., who will serve in an advisory capacity. Currently, Dr. Lister serves as...

June 3, 2024

Developments

OneMedNet inks MSA with top-10 global medtech company

OneMedNet (NASDAQ:ONMD) has entered into a non-exclusive three-year MSA with an undisclosed U.S.-based medical technology company that affects more than 150 million patients worldwide annually. OneMedNet will utilize...

May 30, 2024

Developments

Lucy Therapeutics secures new funding to accelerate innovative Alzheimer’s and Parkinson’s Treatments

Closely-held Lucy Therapeutics (LucyTX) raised $12.5 million in additional funding to further the company’s research programs for Alzheimer’s and Parkinson’s diseases and continue its development of a novel drug target...

May 29, 2024

Developments

BerGenBio announces NCI clinical collaboration with UT Health San Antonio and Swedish Orphan Biovitrum AV

BerGenBio ASA (OSE: BGBIO) has announced that it has entered into a clinical trial agreement with the Mays Cancer Center at UT Health San Antonio and Swedish Orphan Biovitrum AV to study BerGenBio’s selective AXL...

May 29, 2024

Developments

OneMedNet reports greater than five-fold expansion of iRWD network and platform; posts new investor presentation

OneMedNet’s (Nasdaq:ONMD) stock rallied over 208% on more than 420 times average trading volumes today after reporting a greater than five-fold expansion of its proprietary iRWD network and platform through a series of...

May 23, 2024

Developments

Elixir Medical reports positive data from stress system to treat calcified lesions trial

Closely-held Elixir Medical has announced positive results from its PINNACLE I clinical trial evaluating the safety and effectiveness of its novel LithiX Hertz Contact Lithotripsy (IVL) System that uses stress to treat...

May 17, 2024

Developments

Takeda’s dengue vaccine receives WHO prequalification

Takeda (TSE: 4502/NYSE: TAK) TAK-003, a new dengue vaccine, has obtained WHO prequalification. WHO has also recommended TAK-003 for children aged six to 16 in regions that are at risk of the mosquito-borne viral disease...

May 16, 2024

Developments

Profound Medical receives FDA 510(k) clearance for ‘Contouring Assistant’ AI module enabling creation of automated TULSA treatment plan

Profound Medical (NASDAQ:PROF; TSX:PRN) announced that it has received FDA 510(k) clearance for its second TULSA-AI module, Contouring Assistant, a machine learning-based prostate segmentation tool, for use in...

May 14, 2024

Developments

Profound Medical highlights TULSA’s potential to become a mainstream treatment modality across the entire prostate disease spectrum

Profound Medical (NASDAQ:PROF; TSX:PRN) announced that a total of 25 clinical presentations highlighting TULSA procedure’s ability to effectively, safely and efficiently treat an unrivaled variety of prostate cancer...

May 6, 2024

Developments

BioRestorative Therapies and Cartessa Aesthetics collaborate to build a vertically integrated, best-in-class biocosmeceutical platform

BioRestorative Therapies (NASDAQ:BRTX) announced that it has entered into a five-year exclusive supply agreement with Cartessa Aesthetics. The goal of this transformative agreement is to combine BioRestorative’s deep...

April 30, 2024

Developments

PharmaJet creates two SABs

Closely-held PharmaJet created two scientific advisory boards (SABs) – infectious diseases and oncology – comprised of leading pharmaceutical industry experts in immunology, cancer, research, and policy shaping...

April 1, 2024

Developments

AI and precision biologics innovators, iBio and AstralBio, team to build novel best-in-class obesity treatments

iBio (NYSEA:IBIO) entered into a collaboration agreement with AstralBio to discover, engineer and develop novel antibodies to treat obesity and other cardiometabolic conditions. Yesterday, iBio announced a concurrent...

March 27, 2024

BioRestorative Therapies gains media attention for key regenerative medicine programs

OneMedNet forges alliance with clinical trial design and software global leader

Former Hepion CEO sues over departure; cites bad faith dealings with investor

BioRestorative in substantive discussions with prospective licensing partner for ThermoStem metabolic disease program

Sage’s Phase 2 SURVEYOR study meets primary endpoint; reinforces cognitive impact of Huntington’s disease

Viridian reports details of SC VRDN-003 Phase 3 clinical program for patients with TED

OneMedNet joins AWS partner network as it enters into a “stage of anticipated rapid growth”

Inogen shares published study results demonstrating association of portable oxygen therapy with increased survival and cost-effectiveness

Innate Pharma announces positive outcomes from TELLOMAK Phase 2 Study

Trinity Biotech unveils new microsite to highlight distinctive technology and AI-driven platform

Verve Therapeutics appoints Troy Lister as CSO

OneMedNet inks MSA with top-10 global medtech company

Lucy Therapeutics secures new funding to accelerate innovative Alzheimer’s and Parkinson’s Treatments

BerGenBio announces NCI clinical collaboration with UT Health San Antonio and Swedish Orphan Biovitrum AV

OneMedNet reports greater than five-fold expansion of iRWD network and platform; posts new investor presentation

Elixir Medical reports positive data from stress system to treat calcified lesions trial

Takeda’s dengue vaccine receives WHO prequalification

Profound Medical receives FDA 510(k) clearance for ‘Contouring Assistant’ AI module enabling creation of automated TULSA treatment plan

Profound Medical highlights TULSA’s potential to become a mainstream treatment modality across the entire prostate disease spectrum

BioRestorative Therapies and Cartessa Aesthetics collaborate to build a vertically integrated, best-in-class biocosmeceutical platform

PharmaJet creates two SABs

AI and precision biologics innovators, iBio and AstralBio, team to build novel best-in-class obesity treatments

General

More